Sofinnova Investments
Status
ACTIVE
Global HQ
New York, United States
Countries of investment
- USA
Investment stages
- Pre-Seed
- Seed
Industries
About
Sofinnova Investments is a leading clinical-stage biopharmaceutical venture capital firm dedicated to transforming innovative ideas into viable therapeutics. With approximately $3.0 billion in assets under management and a strong commitment to advancing life sciences, Sofinnova leverages its extensive experience and deep industry insights to identify and support groundbreaking companies. By deploying both human and financial capital, Sofinnova plays a pivotal role in fostering the development of promising drug candidates that address unmet medical needs. The firm's strategic investments and collaborative approach enable it to drive significant advancements in healthcare and contribute to the evolution of the biopharmaceutical landscape.
Sofinnova Investments is a leading clinical-stage biopharmaceutical venture capital firm dedicated to transforming innovative ideas into viable therapeutics. With approximately $3.0 billion in assets under management and a strong commitment to advancing life sciences, Sofinnova leverages its extensive experience and deep industry insights to identify and support groundbreaking companies. By deploying both human and financial capital, Sofinnova plays a pivotal role in fostering the development of promising drug candidates that address unmet medical needs. The firm's strategic investments and collaborative approach enable it to drive significant advancements in healthcare and contribute to the evolution of the biopharmaceutical landscape.
Investment Thesis
Invests in biotechnology and life sciences startups with a focus on advanced technologies and innovations.
Manager's Experience
Leveraging extensive experience in the life sciences and technology sectors, the fund manager has successfully completed over 35 investments across North America and Europe. With a strategic emphasis on operator-first approaches, they have facilitated notable exits that underscore their commitment to driving value. Their focus on early-stage ventures allows for the cultivation of innovative companies poised for growth. This data-driven style enhances decision-making and reinforces a robust portfolio that aligns with emerging market trends.
Team
Tiffany Davis
Nathalie Auber
Michael Powell
Leighanne Oh
Jim Healy
Jennifer Jennifer James
James Brody
Hooman Shahlavi
Garheng Kong
Eric Buatois